secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-254838
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Amylyx's RELYVRIO for ALS; Phase 2 trial showed slowed physical decline
--------------------------------------------------------------------------------

- FDA approved RELYVRIO (AMX0035) for adults with ALS based on Phase 2 CENTAUR trial in 137 participants that met primary efficacy endpoint.
- RELYVRIO significantly slowed loss of physical function vs placebo; can be used as monotherapy or with existing ALS treatments.
- Amylyx priced RELYVRIO below the latest FDA-approved ALS product; expects specialty pharmacies to start filling prescriptions within 4-6 weeks.
- Most common adverse events (>=15% and >=5% over placebo) were diarrhea, abdominal pain, nausea, and upper respiratory tract infection.
- Management to host investor conference call Sept 30 at 8:00 AM ET to discuss approval and commercial plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522254838/0001193125-22-254838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522254838/d379888d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-254838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer